Gaps

Challenges and Opportunities in the Biotech Field

The GapSummit 2020 programme, including panels, keynotes and workshops, will be centered on core "gaps" that the field will need to address by 2050. At the conclusion of the conference, Leaders of Tomorrow will be equipped with a holistic understanding of these challenges and have garnered insights to address these challenges in their professional careers.

Global Bioeconomies

It is no exaggeration to say that biotechnology promises to shape nearly every aspect of human life. New biotechnologies have the potential to greatly impact not only the scientific and research activity of a region but also the economies of the countries where they are being discovered and implemented. As barriers to entry into the modern bioeconomy have decreased, there is a greater opportunity for international collaboration and the ability of harness the strengths of bioeconomies from around the world.

In light of the democratization of many biotechnologies, what are the potential pathways available to enter or grow the global bioeconomy? How can new markets be created to nurture talented individuals into leaders who will develop a local biotechnology sector and use these tools to solve problems and address their own challenges? What is the role of government, private enterprise, nonprofits, and other institutions in augmenting biotech growth? What is the appropriate role for international collaborations to help accelerate the development of bioeconomies? What are the specific strengths and challenges associated with the biotech sector in different regions of the world?

In this session, we will investigate these questions with international biotech leaders who have collaborated across continents and have taken active roles in developing the bioeconomy around the world.

Bioentrepreneurship

The products of the modern biotechnology industry are built upon basic science research. Modern academic institutions are increasingly looking for ways to commercialize scientific discoveries in healthcare, agri-tech and white biotech. More researchers than ever before are considering the transition from academia to industry, and many are thinking about building companies around their work. How do we identify what findings and technologies are appropriate targets for commercialization? How can we best form partnerships between academia and industry to benefit from their respective strengths in innovation and commercialization? What should young researchers who are interested in entrepreneurship and science do to prepare for a career at the nexus of biotechnology and business?

In this session, these challenges will be discussed with academics and industry members who have successfully navigated the transition from bench to market in their careers. Funding mechanisms for both industry and academia will be explored. Routes by which academics may partner with commercial entities to enable research as well as means to raising money for an early-career bio-entrepreneur will be discussed with experts at all stages of the scientific pipeline, from startup founder to biotech exec, as well as with funding experts including venture capitalists, angel investors, and startup incubator leadership.

Accelerating Research and Sustainable Innovation

Much of biomedical research in academia and in industry is performed in complex biological systems that are poorly understood. Consequently, research and development within biotech is plagued by high failure rates that limit the rate of progress. In recent years, it has become clear that the current level of productivity is no longer sustainable given the immense cost of R&D. This challenge is manifested prominently in the low success rate of developing preclinical therapy candidates into commercial products, but also occurs across sectors in fields such as agri-tech and white biotech.

In this session, new models for innovation within the biotech industry will be discussed with leading R&D executives as a case study for innovation challenges throughout the industry.

Sustainable Healthcare Economics

Across the planet, the cost of healthcare continues to rise dramatically. The fraction of the gross domestic product devoted to health spending continues to increase, yet increased spending on healthcare is not directly predictive of outcomes. Significant contributors to the increase in medical spending include the cost of drugs, the aging global population, and the more intensive treatment of chronic conditions. It has become increasingly clear that the current healthcare ecosystem is not financially sustainable as it currently exists.

In this session, global challenges in the cost of healthcare will be discussed with healthcare leadership from around the world with a focus on highlighting spaces for innovation.

Digital Health and the Technology Revolution

From the ubiquity of smartphones and wearables to the plummeting cost of DNA sequencing, a revolution in healthcare data science is underway. The advent of such technologies to collect complex multimodal data on individual patients has offered the promise of using population-wide data to better inform and individualize diagnoses and therapeutic plans for specific patients. Indeed, this possibility has piqued significant interest from non-traditional players in the healthcare space who bring deep expertise in machine learning and data science.

In this session, we seek to separate hype from reality and to understand the promise, challenges, and limitations of the role that artificial intelligence and digital health technologies will play in healthcare.

Diversifying Research Landscapes: Delivering to Unmet Needs

According to the United Nations, drug-resistant infections could cause 10 million deaths each year by 2050. Antimicrobial resistance is one of several areas in healthcare that is under addressed by research and innovation in biotech. Other examples include rare and neglected tropical diseases which typically affect the developing world, burdening the poorest of the population and further widening health inequality at a global and local level. How can we diversify research landscapes such that more effort is put into providing therapies for disease areas of high risk and low market volume? What role does government play and how can it incentivize research and innovation in these areas? What models can we create to accelerate research and innovation in areas of unmet need?

In this session, we will discuss how the government can incentivise research and development for areas of high risk and less commercial value. We seek to develop models to cater to these unmet needs in the market.

AgriTech Innovation & Environmental Sustainability

Humanity faces profound sustainability challenges over the next century including climate change, food shortages, water crises, and the depletion of natural resources. Biological solutions hold great promise for solutions to these challenges, but have yet to be deployed at scale.

In this session, current progress towards addressing these problems will be discussed, with a particular focus on the development and design of new biological solutions and their responsible deployment and adoption by society.

Beyond 2050: The Future of Biotech

In this session, global pioneers at the cutting edge of scientific research and industry disruptors will posit their forward thinking visions of the biotechnology industry and opportunities for the next of generation of leaders to advance progress.